EMPAGLIFLOZIN, BI 685509, BI 685509, BI 685509 clinical trials

Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with clinically significant portal hypertension (CSPH) in compensated cirrhosis

This study looks at new ways to treat high blood pressure in the liver, called portal hypertension, in people with liver scarring (cirrhosis). It tests a new drug, BI 685509, alone or with an existing drug, empagliflozin, to see if they can lower this pressure.